
Yahoo · 29 de oct de 2026
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Últimos 235 días · 12/11/25 — 29/10/26
+12.31%
Precio
$ 20.480
Var. %
+2,5%
Volumen operado
222
Precio GSK
US$ 49,51
Teórico (precio / ratio)
GSK ÷ 4
US$ 12,38
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
3,7 %
Frecuencia (estimada)
Trim.
Próxima ex-date
sin fecha
Próximo pago
sin fecha
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 4
USD 0,46
Sí, existe el CEDEAR de GSK (GSK Plc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es GSK.
El ticker del CEDEAR de GSK Plc. en Argentina es GSK. La acción subyacente cotiza en NYSE con el símbolo GSK.
El CEDEAR GSK tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de GSK.
El CEDEAR GSK cotiza hoy a $ 20.480 en pesos argentinos, con una variación diaria de +2,5%.
La acción subyacente GSK (GSK Plc.) cotiza a US$ 49,51 en su mercado de origen (NYSE).
Otros CEDEARs de Salud.

Yahoo · 29 de oct de 2026
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

Yahoo · 29 de oct de 2026
PARMA, Italy, October 29, 2026--Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to i…

Yahoo · 29 de oct de 2026
GSK (LSE:GSK) has released third quarter figures that present a mixed picture. Sales reached £8,887 million, while net income declined to £1,543 million compare…
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 13,17
vs teórico
+6,4%
Cotización MEP implícita
$ 1.555,05
Cotización
US$ 12,37
vs teórico
-0,06%
Cotización Cable implícita
$ 1.655,62
El precio teórico del CEDEAR GSK se calcula dividiendo el precio de GSK por el ratio (4). Hoy resulta en US$ 12,38.
En BYMA podés operar GSK en pesos, GSKD en dólar MEP y GSKC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR GSK en pesos argentinos, con datos de data912.

Yahoo · 28 de oct de 2026
Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says.

Yahoo · 28 de oct de 2026
LONDON (AP) — LONDON (AP) — GSK plc (GSK) on Wednesday reported third-quarter net income of $2.On a per-share basis, the London-based company said it had net in…

Yahoo · 28 de oct de 2026
GSK (NYSE:GSK) reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and…

Yahoo · 28 de oct de 2026
Revenue from GSK's vaccines came up short Wednesday, including the drugmaker's household name shot, Shingrix.

Yahoo · 28 de oct de 2026
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
Noticias vía Finnhub